StockData
ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V. (PRQR) stock

PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 7/30
$1.15−0.03 (-2.54%)

Close on Nov 17, 2026Market cap $121.17MP/E –Yield –

ProQR Therapeutics total assets

Total assets on the balance sheet at the end of each period.

ProQR Therapeutics's total assets was €133.55M at Jun 30, 2026. For fiscal 2025 it was €112.76M, down 32.9% from the year before. The highest annual figure on record is €209.58M in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025€112.76M-32.9%
FY2024Dec 31, 2024€167.96M+21.8%
FY2023Dec 31, 2023€137.88M-19.5%
FY2022Dec 31, 2022€171.32M-18.3%
FY2021Dec 31, 2021€209.58M+112.3%
FY2020Dec 31, 2020€98.73M-16.0%
FY2019Dec 31, 2019€117.54M+6.6%
FY2018Dec 31, 2018€110.23M+107.6%
FY2017Dec 31, 2017€53.10M-19.0%
FY2016Dec 31, 2016€65.54M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026€133.55M-2.9%
Q1 FY2026Mar 31, 2026€99.03M-34.7%
Q4 FY2025Dec 31, 2025€112.76M-32.9%
Q3 FY2025Sep 30, 2025€124.35M+16.4%
Q2 FY2025Jun 30, 2025€137.54M+16.5%
Q1 FY2025Mar 31, 2025€151.69M+22.5%
Q4 FY2024Dec 31, 2024€167.96M+21.8%
Q3 FY2024Sep 30, 2024€106.85M-24.8%
Q2 FY2024Jun 30, 2024€118.05M-20.2%
Q1 FY2024Mar 31, 2024€123.88M-21.6%
Q4 FY2023Dec 31, 2023€137.88M-19.5%
Q3 FY2023Sep 30, 2023€142.03M+16.7%
Q2 FY2023Jun 30, 2023€147.99M-17.3%
Q1 FY2023Mar 31, 2023€158.01M-16.9%
Q4 FY2022Dec 31, 2022€171.32M-18.3%
Q3 FY2022Sep 30, 2022€121.73M-37.7%
Q2 FY2022Jun 30, 2022€179.05M+10.3%
Q1 FY2022Mar 31, 2022€190.23M+92.7%
Q4 FY2021Dec 31, 2021€209.58M+90.2%
Q3 FY2021Sep 30, 2021€195.33M+108.9%
Q2 FY2021Jun 30, 2021€162.36M+56.7%
Q4 FY2020Dec 31, 2020€98.73M-16.0%
Q3 FY2020Sep 30, 2020€110.19M+35.9%
Q2 FY2020Jun 30, 2020€93.50M+3.6%
Q1 FY2020Mar 31, 2020€103.63M-6.0%
Q4 FY2019Dec 31, 2019€117.54M+213.1%
Q3 FY2019Sep 30, 2019€81.06M+52.7%
Q2 FY2019Jun 30, 2019€90.25M+37.7%
Q4 FY2018Dec 31, 2018€110.23M–
Q2 FY2018Jun 30, 2018€37.54M–
Q4 FY2017Dec 31, 2017€53.10M–
Q4 FY2016Dec 31, 2016€65.54M–

More ProQR Therapeutics figures

See a number that looks wrong?